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When my lab sequenced the first
chemokine receptors CXCR2 and CCR1
in 1991, the top BLAST hit for CCR1 was
open reading frame (ORF) US28 of human
cytomegalovirus (HCMV), indicating an
obvious common ancestor and a possible
example of gene piracy. Pox virologists
had already identified virally encoded
TNF and IFN-γ binding proteins, copied
from the host and redeployed as cytokine
scavengers and immune evasion factors;
however, there were no precedents for
G protein-coupled receptors in viruses or
signaling viral immunoreceptor homologs.
Tom Schall, then at Genentech, who had
candidate CC chemokine receptor clones,
learned about our CCR1 discovery and
proposed a collaboration. I told him about
the key features of CCR1: its specificity
for CCL3 and CCL5, as well as monocytes
and lymphocytes, and its sequence homol-
ogy to US28 (1); however, he eventually
wanted to pursue CCR1 independently,
and published it in Cell in fall, 1992 along
with data that US28 could bind to CCL2,
CCL3, CCL4, and CCL5. A month earlier,
our paper had been rejected by Cell for
lack of sufficient binding data; however,
we eventually published our paper in early
1993 in the Journal of Experimental Medi-
cine (1), and the NIH received the patent
for cloning CCR1.
Meanwhile, the complete sequence of
the non-human primate herpesvirus Her-
pesvirus saimiri appeared in 1992, reveal-
ing a CXCR2 homolog known as ECRF3.
Sunil Ahuja, then a post-doc in my lab and
now a Professor at the University of Texas
at San Antonio, used our Xenopus oocyte
expression system to show that ECRF3,
like CXCR2, mobilized calcium in response
to the ELR+ CXC chemokines CXCL1,
CXCL7, and CXCL8, the first example of
a virally encoded chemokine receptor that
signaled (2). My long-time colleague Ji-
Liang Gao, who was a post-doc in my lab at
the time, then showed that US28 was also a
calcium flux signaling receptor for the same
chemokines that Schall’s group had found
bound to US28 (3). Together these papers
pioneered a new field of virally encoded
chemokine receptors that has expanded as
more herpesvirus and poxvirus genomes
have been sequenced. In addition, many
virally encoded chemokines and secreted
chemokine binding proteins were later
identified, along with information about
structure, signaling pathways, biological
functions, and potential disease connec-
tions.
Together, this work demonstrated
unequivocally that the chemokine sys-
tem has been selectively and preferentially
expropriated by these types of viruses;
however, exactly why remains unresolved.
At an evolutionary level, it is remarkable
that the viral chemokine receptors could be
so distantly related to mammalian recep-
tors with which they share ligands, partic-
ularly since this was not the case for the
human chemokine receptors known at the
time, CXCR1, CXCR2, CCR1, and CCR2.
We also began cloning mouse counter-
parts of the human receptors we were find-
ing and noticed that the mouse–human
orthologs were more distantly related than
expected. I decided to investigate this sys-
tematically by doing an in silico study of
the mouse–human orthologs then in the
data base, and found that for the ~500
available sequence pairs, the distribution
of divergence was highly heterogenous.
Most orthologs had high homology, but the
ones that did not were mostly immunoreg-
ulatory factors. I published a paper in
Cell describing this exceptionalism and
proposed that it might relate to evolution-
ary pressure imposed by the predilection of
viruses for this type of host gene (4).
We continued to use homology
cross-hybridization to clone additional
chemokine receptors, including, in 1994,
one we first named CC CKR5 that was
later renamed CCR5. Christophe Com-
badiere, a post-doc in my lab now with
his own lab in Paris, actually cloned
CCR3 and CCR5 cDNAs from the same
screen. He determined their sequences
and leukocyte specificities in parallel, then
investigated their chemokine specificities
sequentially, starting with the eosinophil-
selective CCR3. We reported that CCL3,
CCL4, and CCL5 were agonists for CCR3
in May, 1995, accepted by JBC 1 day after
submission with no revisions (5). How-
ever, colleagues in the field, and ultimately
we were skeptical since CCL3 and CCL4
lacked eosinophil activity. As a check,
Christophe sequenced transfected cDNA
from the original “CCR3” cell lines and,
to our chagrin, found the CCR5 sequence,
not CCR3. Apparently, the plasmid tube
labeled “CCR5” had been mistaken for
“CCR3”. We wrote a correction published
in December, 1995 in JBC indicating that
CCL3, CCL4, and CCL5 were agonists
for a new receptor named CC CKR5. We
then submitted a new paper with the CC
CKR5 sequence, its RNA distribution, and
ligands to JBC, which after an ~6 month
review was rejected in part because the
reviewers regarded it as partly duplicative
of the CCR3 paper.
The same month that our correction
appeared in JBC, Paolo Lusso and col-
leagues in Bob Gallo’s lab at the NCI of NIH
reported in Science that CCL3, CCL4, and
CCL5, the signature ligands for CCR5, were
able to suppress replication of macrophage
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(M)-tropic but not T cell line (T)-tropic
strains of HIV (6). Taken together, the
most obvious and parsimonious hypoth-
esis was that CCR5 was used for M-tropic
HIV infection, but how was unclear to me.
On January 31, 1996, I gave a seminar
at NIH about our new chemokine recep-
tors, concluding with Paolo’s new finding
about HIV-suppressing chemokines and
how CCR5 was an ideal candidate to medi-
ate their action. My colleague Ed Berger
from NIAID and his staff were at the talk,
and Ed emailed me a few days later about
his recent unpublished work identifying
fusin (later identified as a chemokine recep-
tor for CXCL12 and renamed CXCR4) as
the first HIV coreceptor, acting with CD4
at the level of cell entry, and its speci-
ficity for T-tropic strains of HIV (7). He
said he was still looking for a specific HIV
coreceptor for the disease-transmitting M-
tropic HIV and agreed that CCR5 was
the logical candidate. This is how I real-
ized that CCR5 might work at the level
of cell entry, from Ed, and of course his
lab had the assay to test the idea. From
me, he learned about the CCR5 sequence
and its leukocyte and chemokine specifici-
ties that matched Paolo’s chemokine sup-
pressor signature. We provided the plas-
mid to Ghalib Alkhatib, a post-doc in Ed’s
lab, who validated the hypothesis on the
first attempt and highlighted the result by
writing “BINGO!” in his lab notebook.
Meanwhile, Marc Parmentier from
Brussels had beaten us to press with his
own independent cloning and functional
characterization of CCR5, in Biochemistry
on March 19, 1996 (8). This was the
key piece needed to allow four other labs
to join the CCR5-HIV connection frenzy
that year, that started with Paulo’s Science
paper about three CC chemokine suppres-
sors of M-tropic HIV, our JBC correction
reassigning these same chemokines from
CCR3 to the unpublished CCR5 sequence,
followed in February, 1996 by Ed’s pre-
publication announcement of fusin’s T-
tropic HIV coreceptor activity at a Key-
stone meeting. To the astute observer, the
only missing piece to the puzzle was the
CCR5 sequence, provided first by Parmen-
tier. Within 2 weeks of each other in late
June, 1996, all five groups in the hunt pub-
lished papers in Science, Nature, and Cell
that used complementary approaches to
draw the same basic conclusion that CCR5
was an M-tropic HIV coreceptor (9, 10).
Two weeks after that, we published the
sequence of CCR5 with its leukocyte and
chemokine specificities, at last, in the Jour-
nal of Leukocyte Biology (11). The founda-
tional discovery, the first HIV coreceptor
fusin/CXCR4, was published by the Berger
lab 1 month earlier in Science (7). The pace
of discovery and publication had become
breathlessly exciting, and the pages of sci-
entific journals as well as the lay press were
ablaze with stories of the HIV-chemokine
receptor connection, for the new insights
as well as for the potential for new drugs
targeting a host factor in HIV/AIDS.
Ironically, Ed and I had first met sev-
eral years earlier when he came to my
lab to ask about using my oocyte system
to expression clone a putative HIV core-
ceptor from his cDNA library. We never
actually did any experiments then, and
instead ended up with the converse collab-
oration: using my lab’s CCR5 cDNA clone
in Ed’s system to identify the M-tropic
HIV coreceptor. Ultimately, my lab’s con-
tribution was to accelerate the discovery
of CCR5 as the M-tropic HIV coreceptor,
since Ed’s expression cloning system used
to find fusin/CXCR4 would probably have
succeeded in also discovering CCR5.
But what role did these coreceptors
actually play in pathogenesis? My lab took
a lead in answering this next key ques-
tion, through the discovery of CCR5∆32,
the deletion mutant of CCR5, which pro-
vided strong evidence that CCR5 was criti-
cal for HIV transmission at the population
level. I thought that if a common inactivat-
ing CCR5 mutation existed, homozygotes
should be rare among HIV-infected indi-
viduals, but overrepresented among highly
exposed but persistently uninfected indi-
viduals. I proposed the idea of looking
for such a mutation poolside at our kids’
swim meet to my neighbor, good friend,
and colleague Pete Zimmerman, a human
geneticist working as a post-doc at the time
with Tom Nutman in the Laboratory of
Parasitic Diseases of NIAID and now a Pro-
fessor at Case Western Reserve University
School of Medicine. Pete agreed to collabo-
rate, and using a heteroduplex DNA mobil-
ity shift assay for polymorphism detection
he found among 100 blood donors from
the NIH Clinical Center Blood Bank, 21
individuals with a massive shift: 20 het-
erozygotes and one homozygote for what
was eventually named CCR5∆32, which we
later nicknamed “the mother of all muta-
tions in the molecule of the year.” All of
our criteria had been met: it was com-
mon (but restricted mainly to Caucasians),
and the 32 base pair deletion caused
a massive truncation incompatible with
expression and function. Next we received
approval from NIAID’s Division of AIDS
to analyze several thousand DNA samples
from participants in the Multicenter AIDS
Cohort Study (MACS), and we collabo-
rated with HIV/AIDS expert Tony Fauci,
the Director of NIAID, whose laboratory
was right around the corner from mine, to
obtain DNA from two cohorts of long-term
non-progressors and one group of HIV
exposed-uninfected (EU) individuals. As
predicted, compared to the frequency in the
general population, CCR5∆32 homozy-
gosity was markedly increased by about
fivefold in the EU population. However,
our analysis of the critical MACS sam-
ples was delayed by 2 months during which
Steven O’Brien from the NCI of NIH, who
had custody of the MACS samples and
had been directed to send them to us as
well as to Rick Koup at NYU for analy-
sis, conducted his own study of CCR5∆32
in HIV. We finally received the samples
a few weeks before his paper was pub-
lished in Science, and completed our study
validating the second and third parts of
our hypothesis that homozygotes should be
underrepresented from the HIV-infected
population and that heterozygotes would
have a delayed time from infection to the
diagnosis of AIDS. Importantly, homozy-
gotes in the general population appeared to
be healthy. Together, our paper published
in Molecular Medicine, O’Brien’s Science
paper, and papers reporting independent
discoveries of CCR5∆32 by the groups of
Marc Parmentier in Brussels in Nature, and
Rick Koup at the Aaron Diamond AIDS
Research Center in Cell provided strong
proof of principle for targeting CCR5 in
the treatment of patients with HIV/AIDS
(10, 12). Thirteen years later, this discovery
culminated in FDA approval of the small
molecule CCR5 antagonist Selzentry (mar-
aviroc, from Pfizer) for the treatment of
CCR5-tropic HIV. In addition, the “Berlin
patient,” an HIV+ individual who devel-
oped leukemia and was functionally cured
of HIV by a transplant with bone marrow
from a CCR5∆32 homozygote given after
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leukemia chemotherapy, provided proof-
of-principle that targeting CCR5 might
be a cure strategy in HIV/AIDS. The
hope for the future is that cure strategies
will be available for every HIV+ individ-
ual through deliberate genome editing of
CCR5.
Overall, we were pleased that our NIAID
collaborative group contributed the four
main arms for the underlying proof-of-
principle discoveries about CCR5 and HIV:
the independent cloning of CCR5, demon-
stration that CCR5 was an M-tropic HIV
coreceptor, discovery of CCR5∆32, and
demonstration that CCR5∆32 is an HIV
genetic restriction factor at the popu-
lation level. The foundational discover-
ies on which the CCR5 work rested also
came from NIH: Paolo’s discovery at the
NCI of HIV suppressive activity for CC
chemokines (6) and Ed’s discovery at
NIAID of fusin/CXCR4 as the first HIV
coreceptor (7). After this work, my lab went
on to discover the first beneficial role for
CCR5 as a host defense factor in West Nile
virus infection (13, 14).
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